Accelerate Your Preclinical Research By InnoSer’s Innovative Methods.

Customizing in-vitro and in-vivo services for your success.

Recently At InnoSer

InnoSer joins the Eurostars funded project ‘LEMONAID’

LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...

InnoSer meets you at knowledge for growth event

Organized by flanders.bio since it's establishment in 2004, knowledge for growth brings over 1300 biotech, pharma, medtech, agricultural and chemical industry experts and decision makers, as well as investors, universities, topnotch research institutes, policymakers...

InnoSer welcomes Wim Tiest as its Chief Technology Officer

As of April 2020, Wim Tiest has joined InnoSer in the role of Chief Technology Officer (CTO) and as part of the company management team. Wim holds a MSc in biochemical engineering and in artificial intelligence, both from the KU Leuven. He has built his professional...
InnoSer mouse models
THERAPEUTIC AREAS

We Specialize In

Kidney Disease (PKD)

Learn More

Parkinson’s Disease

Learn More

Oncology

Learn More

Alzheimer’s Disease

Learn More

InnoSer’s INNOVATIVE METHODS

Combining In-Vivo And In-Vitro

By our state-of-the-art methods from organoids to genetically engineered mice, we provide reliability and transferability in your results.

Low success rates of drugs that are able to go from bench to the clinic continue to disappoint not only researchers and pharmaceutical companies but also patients and their families. The resulting expenses affect the costs of all drugs that reach the market.

InnoSer cell culture laboratory

This calls for more stringent criteria at the preclinical phase, ensuring only the drugs that are effective and safe for humans continue to the clinical phases. InnoSer excels in combining in vitro and in vivo disease modelling to offer the most reliable screening platforms.

By developing in-vitro technologies and knowledge that offer higher predictive capacity, we support the transition to a world that relies less on animal testing.

GET IN TOUCH WITH US

Tell Us About Your Work

We always keep close contact with our customers to identify and understand their needs better. All our services can be customized for your project requirements.

OUR CLIENTS ABOUT US

Academic And Commercial Expertise

“We truly enjoyed working with the InnoSer team. They bring an outstanding scientific knowledge into the oncology field in combination with high flexibility. InnoSer provided us with and executed a preclinical study project tailored to our needs, and within the agreed timelines. We will definitely work with InnoSer for our future drug development needs.”

 

Ad van de Gorp PhD, CEO Cythura Therapeutics

“Starting a biotech company was something completely new for me. InnoSer supported me in developing the study protocol and with all additional hassle like ethical protocols, logistics, ordering study materials etc. We worked closely with the InnoSer staff and I truly appreciate their professionalism and dedication.”

 

 Joost van Bree, CEO Saillant Therapeutics

Phone

+32 (0)11 14 07 68

Headquarters

InnoSer België NV

Agoralaan A bis
3590 Diepenbeek
Belgium

 

Email

info@innoserlaboratories.com

Subsidiary

InnoSer Nederland BV

Zernikedreef 9
2333 CK Leiden
The Netherlands